At the Biotech Conclave 2026 in Chennai, leading scientists highlighted India's talent and manufacturing strength but stressed the need for sustained funding, predictable regulation, and deep industry‑academia collaboration. Only then can lab discoveries reach patients worldwide.

  • Robust industry‑academia collaboration accelerates innovation.
  • Patient‑character capital and steady funding are essential.
  • Regulatory frameworks must align with global standards.

During a panel at the Biotech Conclave 2026 in Chennai, Dr. Maneesh Paul (Microvioma, Orchid Pharma), Dr. Vasan Sambandamurthy (Bugworks Research India), and Dr. M.M. Balamurali (VIT, Chennai) outlined the roadmap for turning India into a world‑leading biopharma hub.

Dr. Paul recounted the 18‑year journey of the anti‑infective drug enmetazobactam, from a handwritten note in a Chennai lab to market approval. “Discovery is just the first step; financing, development, regulatory clearance and marketing complete the marathon,” he said.

Read Also:Kerala Police Officers Association Opposes Move to Downgrade SHO Posts

Dr. Sambandamurthy emphasized moving “from volume to value,” calling for patient‑character capital, globally‑aligned regulatory processes, a culture of quality, and talent with international exposure.

Dr. Balamurali pointed out the gap between academic research and commercialisation, noting many universities lack manufacturing‑grade infrastructure needed for scale‑up. He urged stronger industry partnerships and dedicated translational research facilities.

Why This Matters

BozokMedia analysis shows that without coordinated industry‑academia ecosystems, India risks losing its competitive edge in the global biopharma race, despite having a large talent pool and manufacturing base.

"Collaboration is the catalyst that turns lab discoveries into life‑saving medicines." – Dr. Maneesh Paul
Did You Know?: India’s biopharma sector is projected to become the world’s third‑largest by 2025, growing at a 12% CAGR.

Frequently Asked Questions

Q1: What are the biggest challenges facing Indian biopharma startups?

A: Limited funding, regulatory uncertainty, and a lack of scale‑up infrastructure are the primary hurdles.

Q2: How can industry‑academia partnerships be accelerated?

A: By establishing joint research hubs, patient‑character capital models, and early‑stage regulator involvement.